Peer-reviewed veterinary case report
Vinorelbine treatment for dogs with bladder cancer after other chemo
By Kaye, M E et al.·Published in Veterinary and comparative oncology·2015·Department of Small Animal Medicine & Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.
- Species:
- dog
Plain-English summary
A group of dogs with urinary bladder cancer that didn't respond to previous treatments were given vinorelbine, a chemotherapy drug, to see if it could help. Out of the 14 dogs treated, two showed some improvement, and eight had stable disease, meaning their condition didn't get worse. Most dogs seemed to feel better overall, and the side effects were mostly mild. On average, the dogs lived for about six months after starting this treatment, suggesting that vinorelbine could be a helpful option for managing this type of cancer in dogs.
People also search for: dog bladder cancer treatment · vinorelbine for dogs · urinary bladder carcinoma in dogs · chemotherapy side effects in dogs
Abstract
The goal of this study was to evaluate the anti-tumour activity and toxicoses of vinorelbine as a palliative rescue therapy for dogs with primary urinary bladder carcinoma. Thirteen dogs refractory to prior chemotherapeutics and one dog naïve to chemotherapeutic treatment were enrolled. Vinorelbine (15 mg m(-2) IV) was administered intravenously along with concurrent oral anti-inflammatory drugs, if tolerated. A median of six doses of vinorelbine (range: 1-16) was administered. Two dogs (14%) had partial responses, and eight (57%) experienced stable disease. Subjective improvement in clinical signs was noted in 11 dogs (78%). Adverse events were mild and primarily haematological in nature. Median time to progression was 93 days (range: 20-239 days). Median survival time for all dogs was 187 days; median survival for 13 pre-treated dogs was 207 days. Vinorelbine may have utility in the management of canine primary urinary bladder carcinoma and should be evaluated in a prospective study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23981116/